Synapse - Works

Results (988)

Belantamab mafodotin (belamaf; GSK2857916) US expanded access program (EAP) for heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM): Baseline characteristics

Meeting Abstract

Hultcrantz, M.; Anderson, L. D. Jr; Anwer, F.; Gasparetto, C.; Kocoglu, M. H.; Lichtman, E. I.; Mo, C.; Niesvizky, R.; Lewis, E.; Li, H.; more...
Clinical Lymphoma, Myeloma and Leukemia (2021)

Fulltext@MSK | Save

MagnetisMM-1: A study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-targeted, CD3-engaging bispecific antibody, for patients with relapsed or refractory multiple myeloma (MM)

Meeting Abstract

Levy, M.; Bahlis, N.; Raje, N.; Costello, C.; Dholaria, B.; Solh, M.; Tomasson, M.; Dube, H.; Damore, M.; Lon, H. K.; more...
Clinical Lymphoma, Myeloma and Leukemia (2021)

Fulltext@MSK | Save

Melflufen plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) exposed or refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies

Meeting Abstract

Rodriguez-Otero, P.; Mateos, M. V.; Oriol, A.; Larocca, A.; Blade, J.; Cavo, M.; Leleu, X.; Nadeem, O.; Hiemenz, J. W.; Hassoun, H.; more...
Clinical Lymphoma, Myeloma and Leukemia (2021)

Fulltext@MSK | Save

HORIZON (OP-106): Melflufen plus dexamethasone in 55 patients with relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD): Subgroup analysis

Meeting Abstract

Richardson, P. G.; Mateos, M. V.; Oriol, A.; Larocca, A.; Cavo, M.; Rodríguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
Clinical Lymphoma, Myeloma and Leukemia (2021)

Fulltext@MSK | Save

Depletion of high-content CD14(+) cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing

Journal Article

Wang, X.; Borquez-Ojeda, O.; Stefanski, J.; Du, F.; Qu, J.; Chaudhari, J.; Thummar, K.; Zhu, M.; Shen, L. B.; Hall, M.; more...
Molecular Therapy - Methods & Clinical Development (2021)

Fulltext@MSK | Save

Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma

Journal Article

Maclachlan, K. H.; Rustad, E. H.; Derkach, A.; Zheng-Lin, B.; Yellapantula, V.; Diamond, B.; Hultcrantz, M.; Ziccheddu, B.; Boyle, E. M.; Blaney, P.; more...
Nature Communications (2021)

Fulltext@MSK | Save

Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b/2 open-label study

Journal Article

Berdeja, J. G.; Madduri, D.; Usmani, S. Z.; Jakubowiak, A.; Agha, M.; Cohen, A. D.; Stewart, A. K.; Hari, P.; Htut, M.; Lesokhin, A.; more...
Lancet (2021)

Fulltext@MSK | Save

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

Journal Article

Piha-Paul, S. A.; Geva, R.; Tan, T. J.; Lim, D. W. T.; Hierro, C.; Doi, T.; Rahma, O.; Lesokhin, A.; Luke, J. J.; Otero, J.; more...
Journal for ImmunoTherapy of Cancer (2021)

Fulltext@MSK | Save

Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial

Journal Article

Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
JAMA Oncology (2021)

Fulltext@MSK | Save

Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma

Journal Article

Jonsdottir, G.; Björkholm, M.; Turesson, I.; Hultcrantz, M.; Diamond, B.; Porwit, A.; Landgren, O.; Kristinsson, S. Y.
European Journal of Haematology (2021)

Fulltext@MSK | Save